38 results about "Rabies" patented technology

This invention discloses a method and apparatus for assessing rabies exposure risk. The method includes: generating a patient information set based on the patient's answers to questions about rabies exposure; analyzing the patient information set using a pre-trained question-and-answer analysis model, and acquiring the patient's wound visual content if the analysis result exceeds a pre-set threshold; assessing the rabies exposure risk based on the wound visual content and the patient information set, thereby enabling a more scientific and accurate rabies exposure risk assessment, providing corresponding treatment suggestions, and generating patient medical records for physician reference, thereby improving physician work efficiency and providing patients with safer, more accurate, and faster medical services.

The invention belongs to the technical field of biology, and particularly relates to a porcine pseudorabies virus gB-gD recombinant fusion protein subunit vaccine as well as a preparation method and application thereof. According to the invention, the PRV gB and gD genes are selected to serially express the gBgD protein to prepare the vaccine, the gB and gD proteins which are respectively expressed are replaced, and the vaccine is high in safety and good in immunogenicity, can effectively prevent the occurrence of a pseudorabies virus virulence enhancement event when being clinically used, provides a powerful space for purification of pseudorabies, and has a wide application prospect.

This invention relates to an anti-swine pseudorabies virus (PRV) preparation and the application of Rehmannia glutinosa polysaccharide in its preparation, belonging to the field of biopharmaceutical technology. This invention provides an anti-swine pseudorabies virus (PRV) preparation comprising Rehmannia glutinosa polysaccharide. It also provides the application of Rehmannia glutinosa polysaccharide in the preparation of an anti-PRV preparation for the prevention and / or treatment of swine pseudorabies. This invention utilizes Rehmannia glutinosa polysaccharide to prevent infection by the PRV variant XJ5 by reducing intracellular oxidative stress levels; it also resists viral infection by affecting viral adsorption. Furthermore, when the concentration of Rehmannia glutinosa polysaccharide is between 50 and 400 μg / mL, it can also affect viral entry and replication, and has no cytotoxicity to PK-15 cells.

The utility model relates to the technical field of farm disinfection, and disclose a pig pseudorabies prevention disinfection structure, including passageway frame, the upper surface fixed connection of passageway frame has the disinfection and killing main part mechanism, the output end fixed communication of disinfection and killing main part mechanism has the spray head, the outside of passageway frame is provided with non -contact disinfection mechanism, and non -contact disinfection mechanism includes two fixed frame, and the inside of every fixed frame all is provided with the shelter door pole. The pig pseudorabies prevention disinfection structure, through passageway frame, disinfection and killing main part mechanism, spray head, fixed frame, shelter door, button controller, warning light, warning device, first infrared distance sensor, second infrared distance sensor, servo motor and rotary lever, passageway frame can be installed at the pig house entrance and exit, and then when the breeding worker enters and exits passageway frame, first infrared distance sensor can monitor that personnel has stood in passageway frame, and second infrared distance sensor can monitor that there is no shelter at two shelter doors.

This study describes the construction, identification, and application of a pseudorabies virus (PRV) triple-gene deletion vaccine strain (gI / gE / TK). Based on the JS-2012-ΔgI / gE double-gene deletion strain, the TK virulence gene was further deleted using CRISPR technology. Its pathogenicity was evaluated in KM mice and piglets, and its immunoprotective efficacy was verified in piglets. This provides theoretical support for the clinical prevention and control of pseudorabies; establishes experimental models in mice and pigs to study the immunoprotective efficacy of the triple-gene deletion strain; and prepares for the subsequent development and evaluation of vaccines using PRV strains as vectors.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a swine fever-porcine pseudorabies bivalent subunit vaccine containing a traditional Chinese medicine immunopotentiator as well as a preparation method and application of the swine fever-porcine pseudorabies bivalent subunit vaccine. The enhancer is prepared by compounding a hypericum perforatum extract and a horse chestnut seed extract, the hypericum perforatum extract and the horse chestnut seed extract are mixed with a classical swine fever virus (CSFV) E2 protein, a pseudorabies virus (PRV) gB protein, a PRV gD protein and an adjuvant to prepare a subunit vaccine, the vaccine can remarkably improve the humoral immunity level and the cellular immunity level excited by the vaccine at the same time, and the vaccine can be used for preparing the vaccine. Specifically, cell factors such as neutralizing antibodies GMT and IFN-gamma are remarkably increased, and the uniformity and stability of immune response are promoted, so that the immunogenicity of the existing swine fever-porcine pseudorabies bigeminy subunit vaccine is effectively improved, and the protection effect of the vaccine is enhanced.

This invention relates to the field of biomedical technology, specifically to a stably expressed porcine pseudorabies virus gD recombinant protein, a vaccine composition, its preparation method, and its applications. The invention provides a stably expressed porcine pseudorabies virus gD recombinant protein, the amino acid sequence of which is shown in SEQ ID NO:7. The porcine pseudorabies virus gD recombinant protein is stably expressed in monoclonal cells, exhibiting stable expression levels after 48 consecutive passages. This lays a solid foundation for its subsequent applications in the preparation of stable porcine pseudorabies subunit vaccine compositions or in porcine pseudorabies virus vaccine efficacy testing formulations.

The present invention provides vaccine compositions, methods and uses thereof, the vaccine compositions are immunogenic compositions of secreted fusion proteins, wherein the secreted fusion proteins comprise a rabies or soluble influenza virus antigen linked by in-frame fusion to a collagen C-terminal portion capable of self-trimerization to form a disulfide-linked trimeric fusion protein. The present invention also provides uses of the immunogenic compositions for generating an immune response against rabies or influenza infection and for use in vaccine compositions. The present invention also provides methods of producing recombinant peptides and proteins, methods of prevention, treatment and / or diagnosis and related kits.

This invention relates to the field of veterinary vaccines, specifically to a porcine pseudorabies virus antigen, a porcine pseudorabies subunit vaccine, its preparation method, and its application. The porcine pseudorabies virus antigen of this invention is the porcine pseudorabies virus gD protein, and the amino acid sequence of the porcine pseudorabies virus gD protein is shown in SEQ ID NO:1. The porcine pseudorabies subunit vaccine prepared using the porcine pseudorabies virus antigen has a simple preparation method, high neutralizing antibody value, and strong antigenic immunogenicity. It can effectively activate the body's immune response and provide excellent immunoprotection against porcine pseudorabies.

This application relates to the technical field of pseudorabies virus detection, specifically to a primer combination for pseudorabies virus detection, its application, and a reagent kit. Specifically, the amplification primers in this application exhibit good specificity and amplification efficiency when used for pseudorabies virus detection, and demonstrate good linear regression performance, enabling more accurate and precise quantitative detection of pseudorabies virus.

The invention relates to an antigen construct for rapid immune detection, in particular to an antigen molecule for realizing dimerization or trimerization through foldon or a variant thereof. The antigen construct can enhance the conformation stability and improve the antibody binding efficiency, so that the sensitivity and shelf life stability in colloidal gold, fluorescent microspheres, ELISA (enzyme-linked immuno sorbent assay) and other in-vitro diagnosis methods in immunochromatography are remarkably improved. The construct is suitable for antibody detection of rabies, influenza, coronavirus, Brucella, tuberculosis and the like in zoonosis and HIV, HBV, HCV, syphilis and the like in human infectious diseases, and can be widely applied to clinical screening, animal quarantine, family self-test and public health emergency monitoring.

The invention discloses a composition containing a G4 stabilizer and a TLS pathway inhibitor and application of the composition. The G4 stabilizer is TMPyP4, the TLS pathway inhibitor is JH-RE-06, and the mass ratio of the G4 stabilizer to the TLS pathway inhibitor is (15-30): 1; the composition can be used for preparing drugs for preventing or treating pseudorabies virus infection or diseases related to pseudorabies virus infection, or can be used for preparing products for inhibiting replication and proliferation of pseudorabies virus or DNA synthesis. Therefore, the invention provides a novel antiviral strategy of blocking virus DNA synthesis through double targets instead of directly acting on virus protein, and provides a new drug research and development path and treatment thought for coping with PRV variants and breaking through the insufficient protection of existing vaccines.

The invention relates to the technical field of antibodies, and discloses an antibody for specifically recognizing porcine pseudorabies virus gE (52-260aa) or an antigen binding fragment thereof and application. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; the antibody can realize specific recognition on gE protein and is used for detecting a target antigen in a sample. The antibody can be used as a core reagent in an immunodetection system, is suitable for laboratory detection and on-site rapid screening of porcine pseudorabies, is beneficial to improving the monitoring efficiency of basic-level and large-scale breeding links, and provides a technical guarantee for early discovery and accurate prevention and control of epidemic situations. Meanwhile, the antibody can also be used as a research tool to be applied to research on gE protein related biological functions and effects of the gE protein in a virus pathopoiesis process, and important support is provided for clarification of virus variation characteristics and optimization of subsequent prevention and control and diagnosis strategies.

This invention discloses a monoclonal antibody against porcine pseudorabies virus gE protein, a hybridoma cell line, and their applications, belonging to the field of biotechnology. The monoclonal antibody 3G10 comprises a light chain and a heavy chain; the amino acid sequence of the variable region of the light chain is shown in SEQ ID NO.1, and the amino acid sequence of the variable region of the heavy chain is shown in SEQ ID NO.8. This invention obtains a hybridoma cell line 3G10 that secretes a specific monoclonal antibody against porcine pseudorabies virus gE protein, and establishes a gE antibody blocking ELISA method and a gE antibody blocking ELISA kit based on the monoclonal antibody 3G10 secreted by this cell line. This method exhibits high sensitivity and specificity for detecting porcine pseudorabies virus gE antibodies, providing a new approach for the monitoring and control of porcine pseudorabies.

The invention relates to application of miR-145-5P in preparation of a medicine for preventing and / or treating PRV (pseudorabies virus) infection related diseases, and belongs to the field of biological medicines. The miR-145-5p is found to be a key differential expression molecule in the PRV infected piglet lung and colon tissue exosome through high-throughput sequencing for the first time. In-vitro cell experiments prove that up-regulation of the expression of the miR-145-5p can significantly play an antiviral role through double mechanisms of inhibiting PRV virus replication and promoting apoptosis of infected cells, and research results of the invention provide a brand new target and strategy for prevention and treatment of PRV.

The application belongs to the technical field of animal disease prevention and control, and discloses application of a traditional Chinese medicine monomer, i.e., a perillyl alcohol, in preparation of a medicine for preventing or treating a pseudorabies of pigs. The application verifies the role of the perillyl alcohol in inhibiting a pig pseudorabies virus infection process and explores the application value of the perillyl alcohol in resisting the pig pseudorabies virus, and provides a theoretical basis and practical guidance for prevention and control of the PRV. In addition, the perillyl alcohol is a natural source medicine, has the advantages of safety, few side effects, low metabolic residues and no pollution, and has good popularization and application value.

The invention relates to the technical field of biological medicines, and particularly discloses a vaccine adjuvant composition as well as a preparation method and application thereof. The vaccine immune composition provided by the invention comprises GM-CSF and cortex albiziae saponin, and has the following advantages: 1, the vaccine immune composition can significantly improve the specific antibody level and the cytokine secretion efficiency, effectively promote the activation of killer T cells, efficiently induce the response of memory T cells, and construct a stable immune defense basis; 2, the immune level of the organism can be remarkably improved after challenge, the tissue injury risk is reduced by inhibiting replication and colonization of viruses in key target organs, and meanwhile, the body weight of the organism is promoted to be quickly recovered after challenge, so that the physiological homeostasis of the organism is better maintained; thirdly, the method is wide in adaptability and can be compatible with various veterinary vaccines such as foot-and-mouth disease vaccines, porcine reproductive and respiratory syndrome vaccines, pseudorabies vaccines and porcine circovirus type 2 vaccines. The method can be applied to the fields of research, development and preparation of vaccine adjuvants or vaccines and the like.

The invention belongs to the technical field of genetic engineering, and particularly relates to a neutralizing monoclonal antibody of a pseudorabies virus gB protein and an antigen epitope peptide and application thereof. An escherichia coli expression system capable of stably expressing the PRV gB protein is designed and constructed, a mouse is immunized by taking the purified gB protein as an immunogen, and the monoclonal cell strain resisting the PRV gB protein is screened through an immunoperoxidase monolayer cell test (IPMA) by utilizing a cell fusion technology and taking the stably expressed gB protein as a detection antigen. The titer of the monoclonal antibody IPMA generated by the cell strain is 1: 32000, the neutralizing titer is 1: 24, the monoclonal antibody can specifically recognize and combine with a 615RVPGERGTC623 sequence region on the gB protein, the interaction between an antigen and the antibody can be known, the monoclonal antibody has important guiding significance on development of vaccines and detection reagents based on the gB protein, and a technical support is provided for prevention, control and treatment of PRV.

The application discloses a fluorescent PCR kit for detecting pseudorabies virus and application, the kit comprises a primer and probe combination for detecting the pseudorabies virus and a primer and probe combination of an internal standard, the nucleotide sequence of the upstream primer for detecting the pseudorabies virus is shown in SEQ ID NO: 7, the nucleotide sequence of the downstream primer is shown in SEQ ID NO: 8, and the nucleotide sequence of the probe is shown in SEQ ID NO: 9; the nucleotide sequence of the upstream primer of the primer and probe combination of the internal standard is shown in SEQ ID NO: 10, the nucleotide sequence of the downstream primer is shown in SEQ ID NO: 11, and the nucleotide sequence of the probe is shown in SEQ ID NO: 12. The minimum detection limit of the kit is 1.5*10 2 copies / mL, which is at least 10 times higher than that of a national standard method, the kit has excellent specificity, and is helpful to realize rapid diagnosis and early prevention and control and reduce the risk of epidemic spread.

This invention belongs to the field of veterinary biological products technology, specifically relating to a chicken-derived serum type 7 of *Rimerella anatipestifer* and its application. *Rimerella anatipestifer* (… Riemerella anatipestifer HD24 has been deposited at the China General Microbiological Culture Collection Center (CGMCC) on March 18, 2026, with accession number CGMCC No. 37707. The inactivated vaccine using the HD24 strain exhibits an 80% immunoprotective rate, demonstrating its good immunogenicity and safety. This provides an ideal candidate strain for the development of inactivated chicken rabies (RA) vaccines, addressing the current shortage and lack of specificity of chicken-derived RA vaccines, and offering a new technical solution for the proactive prevention and control of RA infection in chicken flocks.

The invention provides antibodies, and antigen-binding fragments thereof, that potently neutralize lyssavirus infection and the use of such antibodies. In particular, the invention provides methods of treatment of lyssavirus infection, such as rabies.

The application relates to the technical field of pathogen detection, and discloses a pathogen multiplex PCR rapid detection method based on GenomeLabTM GeXP multiplex gene expression analysis technology. A primer group composed of seven pairs of specific primers, one pair of positive control primers and one pair of universal primers is used to detect pathogens. The seven pairs of specific primers are respectively used for specifically combining with target genes of porcine fever virus, porcine reproductive and respiratory syndrome virus, pseudorabies virus, porcine parvovirus, porcine circovirus type 3, necrotic fusiform bacteria and porcine epidemic diarrhea virus. The 5' end of the universal upstream primer is provided with a fluorescent label. A two-step PCR amplification program is adopted, and rapid and accurate detection of the seven important pathogens, i.e. porcine fever virus, porcine reproductive and respiratory syndrome virus, pseudorabies virus, porcine parvovirus, porcine circovirus type 3, necrotic fusiform bacteria and porcine epidemic diarrhea virus, is successfully realized in one reaction system.

The application belongs to the technical field of immunology detection, and particularly relates to a rabbit monoclonal antibody against a pseudorabies virus glycoprotein gE and application thereof in immunological detection. The amino acid sequences of CDR1, CDR2 and CDR3 on the light chain variable region of the rabbit monoclonal antibody are respectively shown as SEQ ID NO. 3-5, and the amino acid sequences of CDR1, CDR2 and CDR3 on the heavy chain variable region are respectively shown as SEQ ID NO. 8-10. The application provides a rabbit monoclonal antibody against a PRV glycoprotein gE and an immunological detection system constructed by using the antibody, which provides an important technical means for rapid differential diagnosis and large-scale screening of wild-type PRV virus-infected pigs and vaccine-immunized pigs, has the advantages of strong specificity, high accuracy, good sensitivity, simple detection method operation and the like, has a wide application prospect in the field of PRV pathogen purification, and has important application and popularization values.

The invention provides a specific monoclonal antibody for resisting pseudorabies virus IE180 protein as well as a preparation method and application of the specific monoclonal antibody, and belongs to the technical field of biological medicines. The invention provides a hybridoma cell strain pIE180 mAb for producing a specific monoclonal antibody against the pseudorabies virus IE180 protein, and successfully prepares the monoclonal antibody against the PRV IE180 protein. An overlapping peptide library technology shows that the monoclonal antibody can recognize a new B cell epitope, and the epitope is highly conservative in various classic and mutant isolates, can be used for specific detection of PRV infection and development of diagnostic reagents, provides an important molecular basis for design of subunit vaccines, and has broad application prospects. Important clinical application and market prospects are realized.

Disclosed are compositions, vectors, and methods for treating and preventing rabies lyssavirus infection in a subject in need thereof, including rabies lyssavirus encephalitis. The disclosed compositions relate to anti-rabies immunoglobulins and vectors for expressing anti-rabies immunoglobulins such as adeno-associated virus (AAV) vectors that express anti-rabies immunoglobulins in a subject in need thereof. In some embodiments, the disclosed methods relate to treating and / or preventing an infection by rabies lyssavirus in a subject in need thereof, the methods comprising administering to the subject a dose of an adeno-associated virus (AAV) vector that expresses an immunoglobulin that binds and neutralizes rabies lyssavirus in the subject.

The application relates to the technical field of animal infectious disease prevention and control, and particularly discloses application of tetrandrine in preparation of a medicine for preventing and treating pseudorabies of pigs. The application can significantly inhibit the replication efficiency of PRV on Vero cells and IPAM cells. When the concentration of the inhibitor is higher than 4 muM, the progeny virus titer and the virus gene transcription level of PRV are significantly reduced compared with those of a control group, and the pathological changes caused by cell infection are effectively relieved, which indicates that the tetrandrine can effectively inhibit the proliferation of PRV and has a potential application prospect.

The invention discloses a polycarbonate material adjuvant and a preparation method and application thereof, and belongs to the technical field of biological medicine and immunotherapy, the polycarbonate material adjuvant comprises a biodegradable polycarbonate polymer chain segment; the STING agonist is covalently linked to a side chain of a chain segment of the polycarbonate polymer through an amido bond; based on the design thought of degradable polymer-drug coupling, the polycarbonate material adjuvant is slowly hydrolyzed under the action of in-vivo enzyme to release an STING agonist, so that continuous activation of an immune pathway is realized. According to the invention, the STING agonist is combined with the polycarbonate polymer chain segment, so that the continuous activation of the STING pathway is realized, and the cellular immune response is obviously enhanced. The polycarbonate material adjuvant can be gradually hydrolyzed and released in vivo, so that the utilization rate of the medicine in local and drainage lymph nodes is improved, meanwhile, the polycarbonate material adjuvant has good biocompatibility and safety, and a new solution is provided for immunological enhancement of rabies vaccines.

The application discloses an mRNA vaccine mechanism preparation method of pseudorabies virus and belongs to the technical field of biological immunity. The technical scheme is as follows: an mRNA vaccine of pseudorabies virus, wherein the antigen coding sequence of the vaccine is obtained according to the gE protein sequence of the pseudorabies virus. The mRNA vaccine is obtained by taking the gE protein of the pseudorabies virus, which is usually neglected in the preparation of vaccines in the prior art, as the design basis of the antigen. The mRNA vaccine obtained by referring to the design is tested, and the test result shows that the mRNA vaccine is relatively other pseudorabies.